Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ALN-AGT02
- Development stage
- Unknown
- Lead developer
- Alnylam Pharmaceuticals
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Subcutaneous
01
Overview
ALN-AGT02 is a second-generation RNA interference (RNAi) therapeutic being developed by Alnylam Pharmaceuticals in collaboration with Regeneron Pharmaceuticals for the treatment of hypertension. It consists of a small interfering RNA (siRNA) designed to specifically target and silence the messenger RNA (mRNA) for angiotensinogen (AGT), a liver-produced precursor protein that is the sole source of all angiotensin peptides in the renin-angiotensin-aldosterone system (RAAS). By reducing AGT production at its source, ALN-AGT02 aims to provide a potent and durable reduction in blood pressure with infrequent dosing. This program is distinct from Alnylam's first-generation AGT-targeting siRNA, zilebesiran (ALN-AGT), and is currently in early clinical development.
- Other names
- AGT RNAi
02
Targets
AGT (O6-methylguanine-DNA methyltransferase)
Beyond the preview
Go deeper on ALN-AGT02.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ALN-AGT02.